Pfizer mines data to find compounds for repurposing

Collecting and combining data on existing compounds scattered throughout Pfizer (NYSE: PFE) was the challenge facing its global research indications discovery unit. Its goal was to find additional applications for the compounds.

The unit built an information tool that gave researchers access to Pfizer's data assets, according to BioWorld Today. It also built collaboration tools, allowing access to members of the NIH-funded Clinical and Translational Science Awards consortium. The consortium had generated ideas about repurposing old compounds.

The effort has speeded development, with researchers moving five compounds to the clinic over the course of three years. It might even be faster, but for the time required for negotiating agreements on shared intellectual property and licensing.

- here's the article

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.